Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

Pharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved results with limited clinical utility. DNA methylation (DNAm), an epigenetic modification, has been proposed to be involved in both...

Full description

Bibliographic Details
Main Authors: Jiaqi Zhou, Miao Li, Xueying Wang, Yuwen He, Yan Xia, John A. Sweeney, Richard F. Kopp, Chunyu Liu, Chao Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2021.674273/full
id doaj-bbec53c107c74abea33764ec101d9f2c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Jiaqi Zhou
Miao Li
Xueying Wang
Yuwen He
Yan Xia
Yan Xia
John A. Sweeney
Richard F. Kopp
Chunyu Liu
Chunyu Liu
Chao Chen
Chao Chen
spellingShingle Jiaqi Zhou
Miao Li
Xueying Wang
Yuwen He
Yan Xia
Yan Xia
John A. Sweeney
Richard F. Kopp
Chunyu Liu
Chunyu Liu
Chao Chen
Chao Chen
Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
Frontiers in Neuroscience
pharmacoepigenetic
DNA methylation
drug response
schizophrenia
bipolar disorder
major depressive disorder
author_facet Jiaqi Zhou
Miao Li
Xueying Wang
Yuwen He
Yan Xia
Yan Xia
John A. Sweeney
Richard F. Kopp
Chunyu Liu
Chunyu Liu
Chao Chen
Chao Chen
author_sort Jiaqi Zhou
title Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
title_short Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
title_full Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
title_fullStr Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
title_full_unstemmed Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
title_sort drug response-related dna methylation changes in schizophrenia, bipolar disorder, and major depressive disorder
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2021-05-01
description Pharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved results with limited clinical utility. DNA methylation (DNAm), an epigenetic modification, has been proposed to be involved in both the pathology and drug treatment of these disorders. Emerging data indicates that DNAm could be used as a predictor of drug response for psychiatric disorders. In this study, we performed a systematic review to evaluate the reproducibility of published changes of drug response-related DNAm in SCZ, BD and MDD. A total of 37 publications were included. Since the studies involved patients of different treatment stages, we partitioned them into three groups based on their primary focuses: (1) medication-induced DNAm changes (n = 8); (2) the relationship between DNAm and clinical improvement (n = 24); and (3) comparison of DNAm status across different medications (n = 14). We found that only BDNF was consistent with the DNAm changes detected in four independent studies for MDD. It was positively correlated with clinical improvement in MDD. To develop better predictive DNAm factors for drug response, we also discussed future research strategies, including experimental, analytical procedures and statistical criteria. Our review shows promising possibilities for using BDNF DNAm as a predictor of antidepressant treatment response for MDD, while more pharmacoepigenetic studies are needed for treatments of various diseases. Future research should take advantage of a system-wide analysis with a strict and standard analytical procedure.
topic pharmacoepigenetic
DNA methylation
drug response
schizophrenia
bipolar disorder
major depressive disorder
url https://www.frontiersin.org/articles/10.3389/fnins.2021.674273/full
work_keys_str_mv AT jiaqizhou drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT miaoli drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT xueyingwang drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT yuwenhe drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT yanxia drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT yanxia drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT johnasweeney drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT richardfkopp drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT chunyuliu drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT chunyuliu drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT chaochen drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
AT chaochen drugresponserelateddnamethylationchangesinschizophreniabipolardisorderandmajordepressivedisorder
_version_ 1721442461071441920
spelling doaj-bbec53c107c74abea33764ec101d9f2c2021-05-13T08:15:54ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2021-05-011510.3389/fnins.2021.674273674273Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive DisorderJiaqi Zhou0Miao Li1Xueying Wang2Yuwen He3Yan Xia4Yan Xia5John A. Sweeney6Richard F. Kopp7Chunyu Liu8Chunyu Liu9Chao Chen10Chao Chen11Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, United StatesDepartment of Psychiatry, University of Cincinnati, Cincinnati, OH, United StatesDepartment of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, United StatesCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, United StatesCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Animal Models for Human Diseases, Central South University, Changsha, Hunan, ChinaPharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved results with limited clinical utility. DNA methylation (DNAm), an epigenetic modification, has been proposed to be involved in both the pathology and drug treatment of these disorders. Emerging data indicates that DNAm could be used as a predictor of drug response for psychiatric disorders. In this study, we performed a systematic review to evaluate the reproducibility of published changes of drug response-related DNAm in SCZ, BD and MDD. A total of 37 publications were included. Since the studies involved patients of different treatment stages, we partitioned them into three groups based on their primary focuses: (1) medication-induced DNAm changes (n = 8); (2) the relationship between DNAm and clinical improvement (n = 24); and (3) comparison of DNAm status across different medications (n = 14). We found that only BDNF was consistent with the DNAm changes detected in four independent studies for MDD. It was positively correlated with clinical improvement in MDD. To develop better predictive DNAm factors for drug response, we also discussed future research strategies, including experimental, analytical procedures and statistical criteria. Our review shows promising possibilities for using BDNF DNAm as a predictor of antidepressant treatment response for MDD, while more pharmacoepigenetic studies are needed for treatments of various diseases. Future research should take advantage of a system-wide analysis with a strict and standard analytical procedure.https://www.frontiersin.org/articles/10.3389/fnins.2021.674273/fullpharmacoepigeneticDNA methylationdrug responseschizophreniabipolar disordermajor depressive disorder